

Prof. Edward K. Geissler, PhD
Head of Experimental Surgery, Dept. of Surgery
University Hospital Regensburg

Selected Publications: (Current h-Index: 52)

1. Birgit Sawitzki, Paul N Harden, Petra Reinke, Aurélie Moreau, James A Hutchinson, David S Game, Qizhi Tang, Eva C Guinan, Manuela Battaglia, William J Burlingham, Ian S D Roberts, Mathias Streitz, Régis Josien, Carsten A Böger, Cristiano Scottà, James F Markmann, Joanna L Hester, Karsten Juerchott, Cecile Braudeau, Ben James, Laura Contreras-Ruiz, Jeroen B van der Net, Tobias Bergler, Rossana Caldara, William Petchey, Matthias Edinger, Nathalie Dupas, Michael Kapinsky, Ingrid Mutzbauer, Natalie M Otto, Robert Öllinger, Maria P Hernandez-Fuentes, Fadi Issa, Norbert Ahrens, Christoph Meyenberg, Sandra Karitzky, Ulrich Kunzendorf, Stuart J Knechtle, Josep Grinyó, Peter J Morris, Leslie Brent, Andrew Bushell, Laurence A Turka, Jeffrey A Bluestone, Robert I Lechler, Hans J Schlitt, Maria C Cuturi, Stephan Schlickeiser, Peter J Friend, Tewfik Miloud, Alexander Scheffold, Antonio Secchi, Kerry Crisalli, Sang-Mo Kang, Rachel Hilton, Bernhard Banas, Gilles Blancho, Hans-Dieter Volk, Giovanna Lombardi, Kathryn J Wood, **Edward K Geissler**. (2020) Regulatory cell therapy in kidney Transplantation (The ONE Study): A harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. *Lancet*. 395(10237):1627-1639.
2. Riquelme P, Haarer J, Kammler A, Walter L, Tomiuk S, Ahrens N, Wege AK, Goeze I, Zecher D, Banas B, Spang R, Fändrich F, Lutz MB, Sawitzki B, Schlitt HJ, Ochando J, **Geissler EK**, Hutchinson JA. (2018) TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity. *Nat Commun*. 20;9(1):2858.
3. Mycielska ME, Dettmer-Wilde K, Rümmele P, Schmidt KM, Prehn C, Milenkovic V, Jagla W, Madej MG, Lantow M, Schladt MT, Cecil A, Koehl GE, Eggenhofer E, Wachsmuth C, Ganapathy V, Schlitt HJ, Kunzelmann K, Ziegler C, Wetzel CH, Gaumann A, Lang SA, Adamski J, Oefner PJ, **Geissler EK**. (2018) Extracellular citrate affects critical elements of cancer cell metabolism and supports cancer development in vivo. *Cancer Res*.78(10):2513-2523.
4. **Geissler EK**, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Sánchez Turrión V, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ. (2016) Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial. *Transplantation*. 100(1):116-125.
5. **Geissler EK**. (2015) Post-transplantation malignancies: here today, gone tomorrow? *Nat Rev Clin Oncol*. 12:705-717.
6. **Geissler EK**, Hutchinson JA. (2013) Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients. *Curr Opin Organ Transplant*. 18:408-415.
7. **Geissler EK**, Schlitt HJ. (2010) Transplantation: can sirolimus prevent skin cancer in transplant recipients? *Nat Rev Nephrol*. 6:639-641.
8. Schnitzbauer AA, Lamby PE, Mutzbauer I, Zuelke C, Schlitt HJ, **Geissler EK**. (2009) Procedures for ethical review for clinical trials within the EU. *BMJ*. 338:b1893.
9. Brem-Exner BG, Sattler C, Hutchinson JA, Koehl GE, Kronenberg K, Farkas S, Inoue S, Blank C, Knechtle SJ, Schlitt HJ, Faendrich F and **Geissler EK**. (2008) Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. *J Immunol*. 180:335-349.
10. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW and **Geissler EK**. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. *Nat Med*. 8:128-135.